Literature DB >> 25454881

How high is a high risk? Prioritising high-risk individuals in an influenza pandemic.

Jasper Littmann1.   

Abstract

Pandemic contingency plans frequently define priority groups that are given preferential access to influenza vaccine. One of the most commonly named groups for prioritisation is that of high-risk individuals. However, current models of categorisation are unsatisfactory in a number of ways. It will be argued that existing vaccination strategies fail to adequately define what kind of risks are being considered and how, as well as on the basis of which information, these risks are calculated. Moreover, it will be suggested that existing vaccination strategies fail to specify of what magnitude a risk has to be, in order to be categorised as 'high'. Finally, it shall be argued that a mere focus on the size of a risk factor may lead policy makers to overlook underlying concerns of distributive justice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Keywords:  High-risk individuals; Influenza pandemic; Prioritisation; Vaccination ethics

Mesh:

Substances:

Year:  2014        PMID: 25454881     DOI: 10.1016/j.vaccine.2014.10.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Prioritization of COVID-19 vaccination. The added value of the "VALIDATE" approach.

Authors:  Pietro Refolo; Bart Bloemen; Barbara Corsano; John Grin; Iñaki Gutierrez-Ibarluzea; Bjørn Hofmann; Wija Oortwijn; Laura Sampietro-Colom; Lars Sandman; Gert Jan van der Wilt; Dario Sacchini
Journal:  Health Policy       Date:  2022-05-20       Impact factor: 3.255

Review 2.  Prioritising access to pandemic influenza vaccine: a review of the ethics literature.

Authors:  Jane H Williams; Angus Dawson
Journal:  BMC Med Ethics       Date:  2020-05-14       Impact factor: 2.652

Review 3.  Ethics for pandemics beyond influenza: Ebola, drug-resistant tuberculosis, and anticipating future ethical challenges in pandemic preparedness and response.

Authors:  Maxwell J Smith; Diego S Silva
Journal:  Monash Bioeth Rev       Date:  2015 Jun-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.